REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
“ In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion ““...
Coherus' new focus on oncology leads to restructuring, 30% layoffs
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results
Coherus lays off 30% of employees amid new ‘sharpened focus’
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results
Sandoz acquires CIMERLI® business from Coherus
Coherus Completes Divestiture of Ophthalmology Franchise
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (œCoherus or the œCompany, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation...
“ Innovative design enables five-minute pegfilgrastim-cbqv delivery time “ “ Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...